Please read this page before participating in this activity. At the bottom of the page, select “I have read these instructions and understand them,” and then click “Begin Activity.”


Overview

Archive, CME credit no longer available
Release Date: November 2, 2007
Expiration Date: November 2, 2008

This activity consists of audio and visual recording of 8 live presentations. To receive CME credit, please read the overview and follow the link to the presentation.

To view presentation, the learner should click on a presentation title. The Webcast will open in a separate window. The learner may view as many presentations in this activity as he/she chooses. Learner agrees that slides are for webcast viewing only. He or she will not copy, alter, or change these Webcast presentations in any way.

Once 1 or more presentations have been reviewed, learners may link to the CME evaluation from a link at the top of the main index of presentations. This is required for credit. Instructions for the evaluation are found on that page.


Needs and Objectives

Upon completion of this activity, learners will be able to:

• Design antiretroviral strategies that consider current data on:
  
  • Initial antiretroviral therapy and when to start
  • Managing late and complicated failure
  • Incorporating newly approved antiretroviral drugs into patient regimens
  • The status of investigational drugs
  • Emerging metabolic toxicities of HIV and its therapies
• List the major factors impacting management of mental health issues in HIV-infected patients
• Formulate appropriate management strategies for HIV coinfection with acute hepatitis C virus
• Describe the incidence, diagnosis, and management of neurological complications in HIV-infected patients
  

CME Credit

The International AIDS Society–USA is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

The International AIDS Society–USA designates this educational activity for a maximum of 6.0 AMA PRA Category 1 Credits.™ Physicians should only claim credit commensurate with the extent of their participation in the activity.

Physicians who claimed CME credit for attending the live CME course on which this activity is based may not claim credit for participating in this activity.


Intended Audience

This online CME activity is designed for physicians who are actively involved in HIV/AIDS care. Specifically, these activities have been designed for physicians who:

• Have a solid, working knowledge of HIV disease management
• Provide comprehensive or specialty care for at least 10 patients with HIV/AIDS or are involved in HIV/AIDS clinical trials or investigations
• Have completed at least 10 hours of CME in the area of HIV/AIDS medicine in the past 2 years

This activity is also relevant to nurse practitioners, physician assistants, nurses, and other health professionals who provide care to people with HIV disease.


Course Faculty

Chairs

Douglas T. Dieterich, MD, FACP
Course Chair
Professor of Medicine
Department of Medicine
Mount Sinai School of Medicine
New York, New York

Speakers

Roy M. Gulick, MD, MPH
Course Vice-Chair
Volunteer Member, Board of Directors
International AIDS Society–USA
Professor of Medicine
Division of International Medicine and Infectious Diseases
Director, Cornell HIV Clinical Trials Unit
Weill Medical College of Cornell University
New York, New York

Roy M. Gulick, MD, MPH
Course Vice-Chair
Volunteer Member, Board of Directors
International AIDS Society–USA
Professor of Medicine
Division of International Medicine and
Infectious Diseases
Director, Cornell HIV Clinical Trials Unit
Weill Medical College of Cornell University
New York, New York

Carlos del Rio, MD
Volunteer Member, Board of Directors
International AIDS Society–USA
Professor of Medicine
Emory University School of Medicine
Chief of Medical Services
Grady Memorial Hospital
Atlanta, Georgia

David B. Clifford, MD
Melba and Forest Seay Professor of Clinical Neuropharmacology in Neurology
Washington University School of Medicine
Saint Louis, Missouri

Joel E. Gallant, MD, MPH
Volunteer Member, Board of Directors
International AIDS Society–USA
Professor of Medicine and Epidemiology
Division of Infectious Diseases
Johns Hopkins University
School of Medicine
Associate Director of Johns Hopkins
AIDS Service
Baltimore, Maryland

Marshall J. Glesby, MD, PhD
Associate Professor of Medicine and Public Health
Department of Medicine
Division of International Medicine and Infectious Diseases
Weill Medical College of Cornell University
Regional Clinical Director
New York/New Jersey AIDS Education and Training Center
New York, New York

Charles B. Hicks, MD
Associate Professor of Medicine
Duke University Medical Center
Durham, North Carolina

Glenn J. Treisman, MD, PhD
Associate Professor
Director, AIDS Psychiatry Services
Johns Hopkins Medical Institutions
Baltimore, Maryland


Disclosure of Financial Affiliations

In the interest of maintaining the independence of its continuing medical education (CME) activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education, the International AIDS Society-USA requires all persons with control of content (ie; faculty, IAS-USA Board members, and program staff) to disclose any financial relationships that they (or their spouses or partners) have had with commercial companies within the past 12 months of the date of this Web-based CME conference. Any conflicts of interest of those parties are resolved prior to the education activity being delivered.

IAS-USA Board of Directors

Constance A. Benson, MD
Dr Benson received research support from or served as a consultant to Boehringer Ingelheim, Gilead, GlaxoSmithKline, Merck, and Pfizer. She had stock options for Monogram Biosciences and Vertex. (Updated 03/21/07)

Judith S. Currier, MD
Dr Currier received grants and research support from and served as a consultant to Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, and Tibotec. (Updated 03/12/07)

Carlos del Rio, MD
Dr del Rio received grants and research support from GlaxoSmithKline, Merck, and Pfizer. He served as a consultant or was on the speakers’ bureau of Abbott, Merck, and Roche. (Updated 10/09/06)

Joel E. Gallant, MD, MPH
Dr Gallant received grants and research support from Gilead, GlaxoSmithKline, Merck, Pfizer, Roche, and Tibotec, and honoraria from Abbott, Gilead, GlaxoSmithKline, Monogram Biosciences, and Tibotec. He served as a scientific advisor or consultant to Abbott, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Koronis, Merck, Monogram Sciences, Panacos, Pfizer, Schering Plough, Tibotec, and Vertex. (Updated 10/09/07)

Roy M. Gulick, MD, MPH
Dr Gulick received research grants from Gilead, Merck, Panacos, Pfizer, Schering, and Tibotec. He served as a scientific advisor or consultant to Abbott, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Monogram Biosciences, Pfizer, Roche-Trimeris, Schering, Tibotec, and Virco. (Updated 03/05/07)

Donna M. Jacobsen
Ms Jacobsen had no relevant financial affiliations to disclose. (Updated 03/22/07)

Douglas D. Richman, MD
Dr Richman served as a consultant to Achillion, Anadys, Bristol-Myers Squibb, Boehringer Ingelheim, Gilead, GlaxoSmithKline, Idinex, Merck, Monogram, Pfizer, Roche, and Tibotec. (Updated 10/09/06)

Michael S. Saag, MD
Dr Saag received grants and research support from Achillion Pharmaceuticals, Boehringer Ingelheim, Gilead, GlaxoSmithKline, Merck, Panacos, Pfizer, Progenics, Roche, Serono, Tibotec, Trimeris, and Vertex. He served as a scientific advisor to Achillion, Avexa, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Monogram Biosciences, Panacos, Pfizer, Progenics, Roche, Tanox, Tibotec/Virco, Trimeris, and Vertex. (Updated 03/22/07)

Robert T. Schooley, MD
Dr Schooley received and research support and honoraria from or served as a consultant to Abbott, Anadys, Anormed, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Monogram Biosciences, Pfizer, Roche, Schering-Plough, Tanox, Tibotec and Vertex. (05/16/07)

Paul A. Volberding, MD
Dr Volberding served on the advisory boards for Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Pfizer, and Schering, and was on the endpoint adjudication committee of Schering. He received honoraria for speaking from Bristol-Myers Squibb, Gilead, and Vertex. He had stock options for Immune Response Corporation. (Updated 01/22/07)

Course Faculty and Staff

Below are the disclosures of financial relationships of the faculty and program staff of this Web-based CME conference.

Dr Clifford received grants and research support from Bavarian Nordic, NeurogesX, Ortho Biotech, Pfizer, Savient, Schering-Plough, and Tibotec. He served as a consultant to or was on the speakers’ bureaus of Biogen Idec, Boehringer Ingelheim, Elan, Genentech, Genzyme, Millennium, Norvartis, Roche, and Schering-Plough.

Dr del Rio received grants and research support from GlaxoSmithKline, Merck, and Pfizer. He served as a consultant or was on the speakers’ bureau of Abbott, Merck, and Roche.

Dr Dieterich received grant and research support or honoraria from Gilead, GlaxoSmithKline, Roche, and Schering. He served as a consultant or was on the speakers’ bureaus of Gilead, GlaxoSmithKline, Roche, and Schering.

Dr Gallant received grants and research support from Gilead, GlaxoSmithKline, Merck, Pfizer, Roche, and Tibotec, and honoraria from Abbott, Gilead, GlaxoSmithKline, Monogram Biosciences, and Tibotec. He served as a scientific advisor or consultant to Abbott, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Koronis, Merck, Monogram Sciences, Panacos, Pfizer, Schering Plough, Tibotec, and Vertex.

Dr Glesby served as a consultant to Serono.

Dr Gulick received research grants from Gilead, Merck, Panacos, Pfizer, Schering, and Tibotec. He served as a scientific advisor or consultant to Abbott, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Monogram Biosciences, Pfizer, Roche-Trimeris, Schering, Tibotec, and Virco.

Dr Hicks received research grants from Abbott, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Pfizer, Tibotec, Koronis, Gilead, and Schering Plough. He served as a scientific advisor or consultant to Abbott, Bristol-Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Merck, Pfizer, Tibotec, and Monogram Biosciences. He received speaking honoraria from Abbott, Bristol-Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Merck, Pfizer, Tibotec, and Monogram Biosciences.

Dr Treisman was on the speakers’ bureaus of Boehringer Ingelheim and Pfizer.


IAS–USA CME Staff

Ms Jacobsen has no relevant financial affiliations to disclose.

Ms Wilson has no relevant financial affiliations to disclose.


Grant Support

This Webcast activity is sponsored by the International AIDS Society–USA and funded by the International AIDS Society–USA.

Funding for the live activity, upon which this activity was based came from the following commercial companies:

Substantial Grants from:
Bristol-Myers Squibb
Tibotec Therapeutics
Abbott Laboratories
Gilead Sciences
Pfizer Global Pharmaceuticals
Roche Pharmaceuticals

Generous Grants from:
GlaxoSmithKline

Additional grant support for this course:
Merck and Co., Inc.


Discussion of Investigational or Unapproved Usage

This activity presents an update on new research that may involve the use of investigational or unapproved drugs and therapies. Participants should consult the product information and other resources for comprehensive information on drugs and therapies discussed in the cases. The views and opinions expressed herein are those of the faculty and do not necessarily represent the opinions or recommendations of the International AIDS Society–USA.


Contact Information

If you have any questions about this Web-based CME conference activity, please contact the International AIDS Society–USA:

International AIDS Society–USA
425 California Street
Suite 1450
San Francisco, CA 94104-2120
Telephone: 415-544-9400
Fax: 415-544-9401
E-mail: registration2010@iasusa.org

I have read these instructions and understand them.